Sensorimotor Integration in Basal Ganglia Disorders: New Findings on Impaired Kinaesthesia in Focal Dystonia and Parkinson's Disease

2004 ◽  
Vol 35 (03) ◽  
Author(s):  
N Putzki ◽  
P Stude ◽  
K Graf ◽  
M Maschke
1998 ◽  
Vol 13 (3) ◽  
pp. 428-437 ◽  
Author(s):  
Jeffrey M. Hausdorff ◽  
Merit E. Cudkowicz ◽  
Renée Firtion ◽  
Jeanne Y. Wei ◽  
Ary L. Goldberger

Author(s):  
Peggy Mason

The core function of the basal ganglia is action selection, the process of choosing between mutually exclusive actions. Under baseline or default conditions, the basal ganglia suppress movement and prevent more than one movement from occurring simultaneously. The importance of chunking and operational learning is explored through exemplary typing tasks. Pathways through the basal ganglia employ the same input and output ports. Inputs far outnumber outputs from the basal ganglia. Subcortical loops through the basal ganglia are more effective than are cortical loops. The functions of the hyperdirect, direct and indirect pathways to motor control in the skeletomotor loop are detailed. Hemiballismus, Parkinson’s disease, and Huntington’s disease are key basal ganglia disorders. The use of deep brain stimulation (DBS) of the subthalamic nucleus as a treatment for Parkinson’s disease is discussed. Finally, additional basal ganglia loops such as the oculomotor loop are introduced.


2009 ◽  
Vol 25 (1) ◽  
pp. 13-27 ◽  
Author(s):  
Maren Elisabeth Bodden ◽  
Richard Dodel ◽  
Elke Kalbe

CNS Spectrums ◽  
1998 ◽  
Vol 3 (2) ◽  
pp. 36-40 ◽  
Author(s):  
Jau-Shin Lou

AbstractParkinson's disease is the most common basal ganglia disorder that is caused by the degeneration of dopaminergic neurons in the substantia nigra. This article reviews the normal physiology of the basal ganglia in the normal state, as well as the pathophysiology of Parkinson's disease (PD) and other movement disorders associated with the basal ganglia. Also discussed is the pathophysiological basis for the surgical treatment of PD.


1989 ◽  
Vol 28 (03) ◽  
pp. 92-94 ◽  
Author(s):  
C. Neumann ◽  
H. Baas ◽  
R. Hefner ◽  
G. Hör

The symptoms of Parkinson’s disease often begin on one side of the body and continue to do so as the disease progresses. First SPECT results in 4 patients with hemiparkinsonism using 99mTc-HMPAO as perfusion marker are reported. Three patients exhibited reduced tracer uptake in the contralateral basal ganglia One patient who was under therapy for 1 year, showed a different perfusion pattern with reduced uptake in both basal ganglia. These results might indicate reduced perfusion secondary to reduced striatal neuronal activity.


Biomedicines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 368
Author(s):  
Shi-Xun Ma ◽  
Su Bin Lim

Single-cell and single-nucleus RNA sequencing (sc/snRNA-seq) technologies have enhanced the understanding of the molecular pathogenesis of neurodegenerative disorders, including Parkinson’s disease (PD). Nonetheless, their application in PD has been limited due mainly to the technical challenges resulting from the scarcity of postmortem brain tissue and low quality associated with RNA degradation. Despite such challenges, recent advances in animals and human in vitro models that recapitulate features of PD along with sequencing assays have fueled studies aiming to obtain an unbiased and global view of cellular composition and phenotype of PD at the single-cell resolution. Here, we reviewed recent sc/snRNA-seq efforts that have successfully characterized diverse cell-type populations and identified cell type-specific disease associations in PD. We also examined how these studies have employed computational and analytical tools to analyze and interpret the rich information derived from sc/snRNA-seq. Finally, we highlighted important limitations and emerging technologies for addressing key technical challenges currently limiting the integration of new findings into clinical practice.


Sign in / Sign up

Export Citation Format

Share Document